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ABSTRACT The artemisinins are the most effective antimalarial drugs known. They possess a
remarkably wide therapeutic index. These agents have been used in traditional Chinese herbal medicine
for more than 2,000 years but were not subjected to scientiﬁc scrutiny until the 1970s. The ﬁrst formal
clinical trials of the artemisinins, and the development of methods for their industrial scale production,
followed rapidly. A decade later, Chinese scientists shared their ﬁndings with the rest of the world; since
then, a signiﬁcant body of international trial evidence has conﬁrmed these drugs to be far superior to any
available alternatives. In particular, they have the ability to rapidly kill a broad range of asexual parasite
stages at safe concentrations that are consistently achievable via standard dosing regimens. As their
half-life is very short, there was also thought to be a low risk of resistance. These discoveries coincided
with the appearance and spread of resistance to all the other major classes of antimalarials. As a result, the
artemisinins now form an essential element of recommended ﬁrst-line antimalarial treatment regimens
worldwide. To minimize the risk of artemisinin resistance, they are recommended to be used to treat
uncomplicated malaria in combination with other antimalarials as artemisinin combination therapies
(ACTs). Their rollout has resulted in documented reductions in malaria prevalence in a number of African
and Asian countries. Unfortunately, there are already worrisome early signs of artemisinin resistance
appearing in western Cambodia. If this resistance were to spread, it would be disastrous for malaria
control efforts worldwide. The enormous challenge for the international community is how to avert
this catastrophe and preserve the effectiveness of this antimalarial ‘‘magic bullet’’. Drug Dev Res,
71: 12–19, 2010. r 2009 Wiley-Liss, Inc.
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DEVELOPMENT INSIDE CHINA
Discovery and Isolation
Qinghao (‘‘blue-green herb’’) is the Chinese name
for a relatively common plant otherwise known as
Artemisia annua or sweet wormwood. It has been used
as a remedy by Chinese herbalists for more than 2,000
years. The earliest known record was in the book 52
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 c 2009 Wiley-Liss, Inc.Prescriptions, discovered in the Mawangdui tomb of
the Han Dynasty in 168 BC, where it was ﬁrst described
for the treatment of hemorrhoids [Qinghaosu
Antimalaria Coordinating Research Group, 1979;
Klayman, 1985]. The ﬁrst treatment with qinghao of
disease resembling malaria was described around the
second century AD when Zhang Ji, in his text On Cold
Damage, recommended treating ‘‘fevers with sweating
and jaundice’’ with a mixture containing boiled qinghao
[Wilcox et al., 2004]. Around 340 AD, in Hong Ge’s
Handbook of Prescriptions for Emergency Treatment,a
cold extraction method of qinghao was described for
the treatment of intermittent fevers [Klayman, 1985].
Qinghao has also been mentioned in several later
standard Chinese Materia Medica texts as treatment
for fever [Qinghaosu Antimalaria Coordinating Re-
search Group, 1979; Hien and White, 1993]; it has also
been used for lice, wounds, boils, sores, and convul-
sions [Hsu, 2006]. Qinghao has remained in common
use in Chinese herbal medicine [Weina, 2008] up to
the present day.
Formal investigations of the antimalarial proper-
ties of qinghao came as a direct result of the Vietnam
War. In May 1967, Ho Chi Minh made a request to
Zhou Enlai, the then Prime Minister of China, to help
provide new treatments for malaria to reduce its
already high mortality among North Vietnamese
soldiers [Weina, 2008]. In response, the Chinese
government initiated a search for new antimalarial
compounds in an initiative called ‘‘Ofﬁce (or Project)
523’’ [Weina, 2008] involving groups of scientists
throughout China. This involved a systematic examina-
tion of a large number of indigenous plants used in
traditional Chinese remedies [Klayman et al., 1985].
The breakthrough came in 1971 when a low-
temperature method, similar to Hong Ge’s but with
diethyl ether in place of water, was used to produce a
crude extract from qinghao [Hsu, 2006]. This extract
was subsequently shown to possess antimalarial activity
in mice infected with Plasmodium berghei [Hien and
White, 1993]. This was in contrast to the earlier ﬁnding
of the lack of efﬁcacy of boiled qinghao. These results
were ﬁrst ofﬁcially reported in March 1972 [Hsu,
2006]. Animal studies showed no evidence of toxicity in
rats, cats, or dogs when administered in high daily
doses for up to 7 days [Qinghaosu Antimalaria
Coordinating Research Group, 1979]. The active
ingredient of qinghao was isolated in 1972 [Hien and
White, 1993], as a colorless, needle-shaped crystal. In
1975, the name qinghaosu (‘‘active principle of
qinghao’’) was chosen for this new compound along
with the more Western-sounding ‘‘artemisinine,’’ later
changed to ‘‘artemisinin’’ [Klayman et al., 1985]. The
molecular formula for artemisinin (C15H22O5), was
derived from the results of high-resolution mass
spectrometry and elemental analysis, following which
the structure was determined by spectral analysis,
chemical reactions, and X-ray diffraction. It was shown
to be a new type of sesquiterpene lactone with a peroxy
group [Qinghaosu Antimalaria Coordinating Research
Group, 1979]. By 1973, a method had been found to
convert artemisinin to its more active metabolite,
dihydroartemisinin (DHA) [Hsu, 2006], and subse-
quently from DHA to a large number of other
derivatives [Haynes and Vonwiller, 1994]. The endo-
peroxide moiety was found to be essential for
antimalarial activity, and substitutions at the lactone
carbonyl group were found to increase potency [Hien
and White, 1993]. Industrial replication of these
processes, including reduction with sodium borohy-
dride to convert artemisinin to DHA, provided the ﬁrst
opportunity for the large-scale production of artemisi-
nin derivatives from plant materials. Two derivatives in
particular attracted interest, as they were more soluble
and much more active than artemisinin: (1) the oil-
soluble ether derivative, artemether, produced in
Kunming; and (2) the water-soluble hemiester deriva-
tive, artesunate, produced in Guilin [Haynes and
Vonwiller, 1994]. Complex methods have been de-
scribed for the total synthesis of artemisinin and its
derivatives [Zhou, 1986], but these are not cost
effective for large-scale production [Klayman et al.,
1985]; thus, the artemisinins continue to be of plant
origin.
Development as Monotherapy
In 1972, 21 patients with Plasmodium falciparum
and vivax malaria were successfully treated using the
diethyl ether extract of qinghao in Beijing [Hsu, 2006].
Different extractions of qinghao were used successfully
from 1974–1978 in a large multicenter trial of 2,099
patients with malaria (1511 of these had P. vivax and 558
P. falciparum, including 143 with chloroquine resistant,
and 141 with cerebral, malaria) [Qinghaosu Antimalaria
Coordinating Research Group, 1979]. Artemisinin
produced a rapid clinical cure (clearance of fever and
asexual parasites in the blood) in almost all patients,
without obvious toxicity, and a faster parasite clearance
than quinine in cerebral malaria. However, there were
high recrudescence rates of around 10–25%.
It was not until 1979 that Chinese scientists ﬁrst
published clinical ﬁndings for the artemisinin anti-
malarials in an international scientiﬁc journal, the
Chinese Medical Journal, in a paper entitled ‘‘anti-
malarial studies on qinghaosu’’ [Qinghaosu Anti-
malaria Coordinating Research Group, 1979]. This
paper summarized much of what was known about the
chemistry, pharmacology, and clinical efﬁcacy of the
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animal studies, and human trials, and was the ﬁrst time
this new group of antimalarials came to the attention of
the West. At that time, however, China was a relatively
closed country, and there was great skepticism in the
West that a previously unknown natural remedy could
be so effective [Weina, 2008]. Furthermore, manufac-
turers of artemisinin drugs in China did not meet
international standards for Good Manufacturing Prac-
tice (GMP) [Wright, 2002]. Bodies such as the World
Health Organization (WHO) were not sufﬁciently
convinced by the available research results to recom-
mend the artemisinins at that time for the treatment of
malaria.
Since 1979, a number of other Chinese clinical
trials investigated the efﬁcacy of oral, intramuscular,
and intravenous artesunate, intramuscular artemether,
and oral dihydroartemisinin. Very little of this trial data
has been published outside of China, one exception
being studies by a group in Guangzhou. In total,
artemisinins were administered to 2,150 cases with
P. falciparum (including 91 with severe disease), and
105 cases of P. vivax malaria. These compounds were
found to be rapidly effective with recrudescence rates
of 5–10% following 5- to 7-day treatment courses and
there was little evidence of toxicity [Li et al., 1994].
In October 1981, at the Fourth Meeting of the
Scientiﬁc Working Group on the Chemotherapy of
Malaria of the WHO, in Beijing, Chinese researchers
summarized the research results to date on the
antimalarial qinghaosu and its derivatives. WHO
representatives were very impressed by what they
heard. They approached the Chinese government for
samples of the plant and details of the extraction
techniques to verify the Chinese ﬁndings. However, the
Chinese representatives were reluctant to share these
details and further collaboration did not occur at that
time [Qigui et al., 2007].
DEVELOPMENT OUTSIDE CHINA
Conﬁrmation and Toxicity Studies
As a result of the caution expressed by the
Chinese, a group of scientists from the U.S. Army’s
Division of Experimental Therapeutics, Walter Reed
Army Institute of Research (WRAIR), began a search
for the plant in the United States. They attempted to
replicate the extraction of artemisinin from Artemisia
annua serendipitously discovered growing in Virginia
and near Washington DC, supplemented by material
from the U.S. National Arboretum. In 1984 they ﬁnally
succeeded and published their ﬁndings, including its
extraction with petroleum ether, chromatographic
separation, and potent antimalarial activity against
chloroquine sensitive and resistant strains of
P. falciparum in vitro [Klayman et al., 1984]. During
the following years, much of the earlier Chinese work
was replicated and the remarkably high efﬁcacy of the
artemisinins against malaria in vivo was conﬁrmed. In
Thailand and Vietnam, a number of studies conducted
between 1987 and 1994 also conﬁrmed the Chinese
ﬁndings of high efﬁcacy and low toxicity [Hien, 1994;
Looareesuwan, 1994]. However, a series of animal
experiments by another group at the WRAIR, using
artemotil (arteether) and artemether and published in
1994, showed that these drugs could produce fatal
neurotoxicity in high dose, causing brain damage in rats
and dogs [Brewer et al., 1994]. This ﬁnding caused
some organizations to lose interest in these compounds.
However, this neurotoxicity has since been shown not
to occur with the water-soluble derivatives, such as
artesunate, and no correlate of the animal pathology
has been reliably demonstrated in humans [White,
2008].
Treatment of Severe Disease
Parenteral artemether has to be given by
intramuscular injection, as it is soluble in oil but not
in water. Its bioavailability is thus more variable than
intravenous artesunate due to its slow and erratic
absorption, and it is perhaps not surprising that it is a
less effective antimalarial, particularly in severely ill
patients. However, several randomized trials during the
1990s and early 2000s showed it to be equally
efﬁcacious to intravenous quinine [Artemether-Qui-
nine Meta-analysis Study Group, 2001], although a lack
of superiority over quinine hindered its further
development.
Because of its solubility in water, artesunate is the
only compound that is suitable for intravenous injection
for use in patients with severe disease. In 2005, the
results of a large multinational antimalarial treatment
trial of severe malaria were published, the SEAQUA-
MAT study [Dondorp et al., 2005]. This was a
randomized trial in predominantly Asian adults of
intravenous quinine versus intravenous artesunate.
This trial found a 34.7% lower mortality in patients
who received artesunate rather than quinine. As a
result, the 2006 WHO Guidelines [World Health
Organization, 2006] were changed to include, for the
ﬁrst time, intravenous artesunate as the recommended
ﬁrst-line treatment for severe malaria. This replaced
quinine for low transmission settings and was recom-
mended as an alternative to quinine for children in
high transmission settings. Initially, due to concerns
about possible toxicity in humans, based on the
previous animal studies, the dose of intravenous
artesunate was kept low, but in this guideline it was
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neurotoxicity in the SEAQUAMAT study, and a
subsequent detailed study showed no effect of
intravenous artesunate on the heart [Maude, 2009a].
A subsequent multicenter trial based on the SEAQUA-
MAT design is currently underway in African children
[Day and Dondorp, 2007].
Rectal preparations of artemisinins are also
available for situations where parenteral therapy is
not immediately available; a single dose of pre-referral
rectal artesunate has recently been shown to reduce
mortality when access to injections will take several
hours [Gomes et al., 2009].
Combination Therapy
Two disadvantages of the artemisinins when used
as monotherapy are the relatively high recrudescence
rate of around 10% and the need for a 7-day course
(with associated poor compliance) in order to achieve
radical cure [White, 2008]. One solution to these
problems is to use the drug in combination with a
second antimalarial, the so-called artemisinin combina-
tion therapies (ACTs). With ACTs, the duration of
treatment is only 3 days and the exposure of parasites
to artemisinin monotherapy is minimized, reducing the
likelihood of artemisinin resistance.
Because of spreading meﬂoquine resistance
around the Thai–Burmese border area, artesunate–me-
ﬂoquine ACT was introduced as a replacement for
meﬂoquine monotherapy in Thailand during the early
1990s [Nosten et al., 1994]. This was the ﬁrst large-scale
use of an ACT in the ﬁeld. A series of clinical studies
showed this new regimen to have extremely high cure
rates, to have successfully halted the spread of me-
ﬂoquine resistance and reduced the incidence of malaria
[Nosten et al., 2000]. It continues to be used there today
as two separately formulated medications, and a ﬁxed
dose combination has recently become available.
Chinese researchers at the Beijing Academy of
Military Medical Sciences during the 1980s combined
oral artemether with another drug they had developed,
benﬂumetol (lumefantrine), as a treatment for non-
severe malaria. In 1990, Chinese ofﬁcials came to an
agreement with Swiss pharamaceutical company No-
vartis (then Ciba-Geigy) to work together to develop,
test, and manufacture this artemisinin combination
therapy, later called Coartem. Novartis assisted their
Chinese partners to redesign local production facilities,
upgrade their quality assurance systems, and construct
new factories to ensure compliance with GMP
standards. Novartis acquired the rights to market the
therapy outside China in 1994, although Chinese
companies continue to supply the raw material for
the drug to Novartis, and China continues to hold a
domestic patent for the therapy. Today, Coartem is
produced by Novartis in China and the United States
and is the most widely used artemisinin combination
worldwide. Food and Drug Administration (FDA)
approval was given for use of artemether-lumefantrine
in the United States in April 2009. This ACT has the
advantage of being one of few coformulated ACTs to be
produced to international GMP standards, and it is
therefore on the WHO list of pre-qualiﬁed medications.
Coformulation means both drugs are combined in the
same tablet; this is designed to prevent patients from
taking only the artemisinin component to avoid side
effects from the partner drug, a particular problem with
artesunate-meﬂoquine. The other major coformulated
ACT is dihydroartemisin-piperaquine (DHA-PQP), and
this has been shown to be a safe, well tolerated,
and highly effective treatment of P. falciparum malaria
in Asia and Africa [Zwang et al., 2009]. DHA-PQP has
not yet been conﬁrmed to be manufactured in
accordance with GMP standards, although prequaliﬁca-
tion is currently under way. Hence, artemether-
lumefantrine remains the drug of choice recommended
by the WHO for uncomplicated malaria.
Together with their partners, the Drugs for
Neglected Diseases initiative have recently developed
two other coformulated ACTs: artesunate-amodiaquine
(ASAQ/Coarsucam) and artesunate-meﬂoquine (ASMQ).
ASAQ was introduced in 2007 and joined artemether-
lumefantrine as the only other WHO prequaliﬁed ACT.
It has the advantage of once a day administration and is
now available in 24 countries in sub-Saharan Africa.
ASMQ was ﬁrst used in Brazil in 2008 and will be
introduced to other countries in South America and
Southeast Asia over the next few years.
Oral ACTs have been shown in a number of
clinical trials over the past decade to be the most
effective antimalarials for uncomplicated disease
[Mayxay et al., 2004; Stohrer et al., 2004; Guthmann
et al., 2005; van den Broek et al., 2005; Piola et al.,
2005; Falade et al., 2005; Stepniewska et al., 2004;
Mutabingwa et al., 2005]. A large body of clinical and
trial experience has also reassured the international
community of the very low toxicity of the artemisinins.
Because of concerns about resistance having arisen to
all major classes of antimalarials other than the
artemisinins, and the desire to preserve the effective-
ness of the artemisinins, the WHO chose to switch
policy in 2004 to recommend ACTs as treatment for
malaria in areas where resistance to antimalarial
monotherapies had arisen (chloroquine, sulfadoxine/
pyrimethamine, and amodiaquine) [Roll Back Malaria,
2004]. In 2006, they became recommended ﬁrst-line
treatment for uncomplicated P. falciparum malaria
worldwide [World Health Organization, 2006].
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By May 2008 only 11 countries had not yet
adopted ACT for ﬁrst-line treatment of uncomplicated
disease due to P. falciparum [World Health Organiza-
tion, 2008a]. Unfortunately, there are still few produc-
tion facilities approved to international GMP standards
that can manufacture ACTs so that demand continues
to exceed supply. There have also been problems with
falsely inﬂated purchase costs, fake artemisinins in Asia
[Dondorp et al., 2004; Newton et al., 2006], and Africa
and poor quality control within certain batches of drug.
In addition, available supplies of these drugs have been
insufﬁcient to meet demand in the developing world;
thus, market prices of ACTs are many times higher
than the now almost useless chloroquine and sulfadox-
ine-pyrimethamine [Woodrow et al., 2005]. New
initiatives by the Global Fund, WHO, Gates Founda-
tion, and Roll Back Malaria, among others, to
encourage the increase in production and subsidize
costs are helping to remedy this situation. There are
also a number of new synthetic artemisinin derivatives
and ACTs currently under development [Olliaro and
Wells, 2009].
The vast majority of intravenous artesunate is still
produced in China and Vietnam and it is not widely
available elsewhere [Anstey et al., 2006]. The major
hurdle is that none of the production facilities in these
countries are GMP-certiﬁed and thus cannot be
licensed by many national bodies [Anstey et al.,
2006]. It is also difﬁcult to secure sufﬁcient quantity
of supply. Only Brazil, China, Iran, Lao, Myanmar,
Papua New Guinea, Solomon Islands, Thailand, and
Vietnam have so far adopted artesunate as national
treatment policy for severe malaria [World Health
Organization, 2008c]. In 2006, intravenous artesunate
replaced quinine as ﬁrst-line treatment for severe
disease in the national Therapeutic Guidelines of
Australia, where it remains unlicensed but is available
under a Special Access Scheme [Anstey et al., 2006]. It
is also available on a named patient basis in the United
Kingdom and United States. Until GMP-certiﬁed
artesunate becomes more available, this situation is
unlikely to change.
ARTEMISININ RESISTANCE
Antimalarial resistance can be detected as re-
duced in vivo or in vitro responses, or via use of
molecular markers proved to mediate drug resistance.
Because artemisinins are used predominantly in
combination with other drugs (as ACTs), measures of
parasite clearance are more sensitive markers of
reduced susceptibility than recrudescence rates (which
are inﬂuenced strongly by resistance to the partner
drug). Until recently, there has been no evidence for a
signiﬁcant reduction in artemisinin efﬁcacy at either
clinical or in vitro levels. In broad terms, the rapid
antimalarial action of artemisinins, combined with their
pharmacokinetic properties (with terminal elimination
half-lives in the order a few hours), led to the belief
that resistance to artemisinins would be very slow to
develop since exposure of parasites to subtherapeutic
levels of drug would be very brief. However, in 2006,
the WHO issued an ultimatum to providers to stop
selling artemisinins as monotherapy to reduce the risk
of resistance arising and increase the useful lifespan of
this class of antimalarials [Nelson, 2006]. In fact,
artemisinins had already been widely available as
monotherapy for many years in a few countries. In
Cambodia, artemisinin monotherapies were ﬁrst intro-
duced from China more than 30 years ago [White,
2008]. For most of the period since then, they have
been available through the private sector in subther-
apeutic doses due to inappropriately abbreviated
treatment courses [Yeung et al., 2008], poor quality
manufacture, or combination with fake drugs [Newton
et al., 2006]. Thus many malaria sufferers in Cambodia
received artemisinin monotherapies that failed to cure
their infection. This combination of continuously
multiplying parasites in the presence of nonlethal drug
levels produces ideal conditions for the generation of
artemisinin resistance [Stepniewska and White, 2008;
Maude et al., 2009b; Pongtavornpinyo et al., 2009].
Cambodia was one of the ﬁrst countries to switch
ﬁrst-line treatment to ACT in national antimalarial
drug policy (artesunate-meﬂoquine in 2000) [Yeung
et al., 2008], and a blanket ban on the use of
artemisinin monotherapies has recently been intro-
duced there.
Since 2003, there have been isolated reports of
high failure rates and reduced in vitro responses to
artemisinins in parts of Asia [Vijaykadga et al., 2006;
Yang et al., 2003; Jambou et al., 2005; Denis et al.,
2006a,b]. In December 2008, it was reported that there
were prolonged parasite clearance times, despite
adequate drug levels, in 2 out of 60 cases of falciparum
malaria in a study in Cambodia [Noedl et al., 2008].
This was followed in mid-2009 by a detailed report
describing markedly prolonged time to parasite clear-
ance in patients treated with artesunate in Pailin,
Cambodia [Dondorp et al., 2009]. The reduced
parasitologic response could not be explained by
pharmacokinetic or other host factors. The most likely
explanation for this very concerning ﬁnding is infection
with P. falciparum that is to some degree resistant to
artesunate. Inappropriate use of artemisinin mono-
therapies is probably at least partly responsible for this
resistance having arisen ﬁrst in Cambodia, particularly
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practice is not unique to Cambodia [Burki, 2009],
however, and the lack of any robust signs of resistance
elsewhere suggests that there are likely to be other
contributory factors. If no action is taken, it is
likely that this mildly resistant phenotype will become
increasingly resistant and ultimately spread elsewhere.
Previously, chloroquine and sulfadoxine pyrimetha-
mine-resistant malaria ﬁrst arose in Cambodia and
subsequently spread across the world [Roper et al.,
2004; Verdrager, 1986]. With the ongoing increase in
ease of traveling between distant places, the potential
for rapid spread of such phenotypes is greater now than
it has ever been. By negating the hugely beneﬁcial
contribution of artemisinin combination therapies,
artemisinin-resistant malaria, wherever it appears,
would be a disaster for malaria control and elimination
efforts.
Molecular detection of artemisinin resistance has
remained compromised by the fact that the mechanism
of action of this group of compounds is still not well
understood. The organellar location of their antimalar-
ial action, and the physical nature of their target and
how they interact with it, represent some of the
greatest controversies in current malaria biology
[Fidock et al., 2008]. Ampliﬁcation of the P. falciparum
multidrug resistance gene Pfmdr1 is associated with
increased IC50 values for artemisinins [Price et al.,
2004], but the effect is small and is clearly not
associated with reduced in vivo susceptibility; parasite
clearance rates remain unchanged in parasites with
multiple copies of Pfmdr1.
PRESERVING THE MAGIC BULLET
To avoid the doomsday scenario of global spread of
artemisinin resistance, there must be urgent interven-
tion in Western Cambodia. In response to the
preliminary results from Pailin and elsewhere, the
WHO convened a series of meetings to discuss how to
proceed. It was agreed that containment of artemisinin
resistance would involve removing selection pressure
and reducing and ultimately eliminating falciparum
malaria in Western Cambodia. Strategies being con-
sidered include prohibiting the use of artemisinin
monotherapy and introducing an alternative, such as
dihydroartemisinin-piperaquine or atovaquone-progua-
nil, as treatment or in a mass screen-and-treat campaign,
in combination with insecticide treated bednets [World
Health Organization, 2008b,c,d]. In the absence of
sufﬁcient data and time in which to collect it,
mathematical modeling is being employed to help
inform these decisions [Maude et al., 2009b,c].
CONCLUSION
Currently there is a paucity of promising novel
antimalarial drugs under development and a loss of the
artemisinins to resistance would be a disaster for
international malaria control. With the most effective
and least toxic antimalarial known still in our arsenal, in
combination with far more effective vector control
measures than ever before, we currently have the best
opportunity in history to eliminate—and, it is hoped,
eradicate—malaria. It would be a tragedy if we were to
squander this opportunity by failing to preserve the
artemisinins as a ‘‘magic bullet’’ against malaria.
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